A synthetic steroid with durabolin 25 progestogenic activity. It has no androgenic and estrogenic activity. It inhibits the secretion of gonadotropins (LH especially). In small doses, it inhibits ovulation. It has an inhibitory effect on the processes required to prepare the endometrium for implantation of the fertilized ovum and increases the viscosity of cervical mucus. Reduces vasomotor symptoms during menopause.In high doses, it has antitumor effect in hormone-malignancies. This effect is due to the drug, presumably durabolin 25 by the action of steroid hormone receptors on the pituitary-gonadal system.Plasma protein binding is 90-95%. It penetrates through the blood-brain barrier, excreted in breast milk. It is metabolized in the liver. The half-life is about 30 hours. It is deduced with bile and urine as metabolites and unchanged.
recurrent and / or metastatic endometrial cancer, kidney cancer, hormone-dependent breast cancer forms in postmenopausal women.
Dosing and Administration
Dose Tsiklotala is determined individually and depends on the evidence and the applicable treatment regimens.
In cancer, endometrial and kidney cancer drug taking 200-600 mg per day, in breast cancer – according to 400-1200 mg per day. The daily dose is divided into 2-3 doses. Treatment continued until signs of progression of cancer.
The frequency of side effects is classified in accordance with the recommendations of the World Health Organization:
very often – at least 10%,
often – at least 1% but less than 10%;
infrequently – at least 0.1% but less than 1%,
rare – less than 0.01% but less than 0.1%;
very rare (including isolated cases) – less than 0.01%.
Immune system: infrequently -anafilakticheskaya reaction, skin rash, itching; rarely – urticaria, erythema.
From the nervous system: often -Head pain, anxiety, irritability, sleep disturbance, drowsiness, fatigue, depression, dizziness.
Since the cardiovascular system: rarely – increased blood pressure; -tromboembolicheskie rare disorders.
On the part of the organ of vision: rarely – acute visual disturbances, diplopia, exophthalmos.
The respiratory system, organs, thoracic and mediastinal disorders: rarely – pulmonary embolism.
Skin and subcutaneous tissue disorders: uncommon – acne. chloasma (hyperpigmentation of the skin in the form of yellowish-brown spots), alopecia.
From the gastrointestinal tract: often – nausea, jaundice rarely -holestaticheskaya.
Reproductive system and breast: often – increased sensitivity of the nipple and breast milk, breast tenderness; rarely – galactorrhea, menstrual disorders, erosion and changes in vaginal discharge, amenorrhea.
Other: rarely – weight gain, fatigue, syndrome Cushing (obesity, moon face, striae of different colors, lower limb edema, decreased libido, hyperpigmentation of the skin in areas of friction, decreased glucose tolerance and increase blood pressure), hyperthermia, liver dysfunction, rarely – hirsutism, cramps in the calf muscles.
Hypersensitivity to durabolin 25 or any other components of the drug; pregnancy; breastfeeding; acute and chronic heart failure in the stage of decompensation; thrombophlebitis and other thromboembolic complications, including the anamnesis; severe liver disease, including cholestatic jaundice, hepatitis, liver tumors, Rotor syndrome, Dubin-Johnson syndrome; porphyria; bleeding from the vagina and urinary tract unknown etiology; lactose intolerance; Lactase deficiency; glucose-galactose malabsorption.
of stroke (increased risk of developing, or in history), hypercalcemia, epilepsy, migraine, asthma, renal insufficiency, hypertension, diabetes, depressive disorders in history.
Interaction with other medicinal products
In an application with aminoglutethimide bioavailability of durabolin 25 reduced. durabolin 25 can increase the effects of anticoagulants. While the use of anticonvulsant drugs (carbamazepine, phenytoin, phenobarbital), antibacterial drugs (rifampicin, rifabutin, efavirenz) and other inducers of cytochrome P450 isoenzyme system increased activity of metabolic processes.
A specific antidote is not known. Treatment is symptomatic.
With the development of acute visual disturbances, up to the total or partial loss of vision, diplopia, migraine and exophthalmos Verapleks receiving the drug should be discontinued immediately. In these cases it is necessary to conduct a thorough ophthalmic examination to detect edema papilla of the optic nerve or retinal vascular lesions.
When thrombosis and thromboembolic complications (thrombophlebitis, pulmonary embolism, stroke, thrombosis, retinal vein) drug therapy should be discontinued Verapleks.
At higher doses Verapleks (500 mg or more) may adrenal suppression. After discontinuation of the drug may develop Verapleks adrenal insufficiency. Verapleks drug can cause fluid retention, so it is possible worsening of epilepsy, migraine, asthma, heart disease or kidney disease.
Patients with a history of depressive disorders in receiving medication Verapleks should be under medical supervision. When symptoms of depression therapy with Verapleks should be discontinued.
Verapleks drug can reduce glucose tolerance, so diabetic patients receiving the drug Verapleks need regular monitoring of blood glucose concentration.
Patients receiving long-term therapy with Verapleks, you should periodically monitor liver function and endocrine organs.
During the cytological or histological examination of endometrial or cervical cancer, a pathologist must notify the therapy drug Verapleks.
Against the background of the drug Verapleks to change the results of the following research: determining the concentration of gonadotropins; determination of the concentration of progesterone, cortisol, testosterone (male), estrogen (in females) in the blood plasma; determining pregnanediol concentration in urine; conducting tests with a load of sugar; conducting the test with metapyron.
Effects on ability to drive vehicles and machinery
With the development of adverse reactions from the central nervous system, patients should exercise caution when performing activities that require high concentration and speed of psychomotor reactions. Running low dose t3 clen cycle trying to lose bodyfat isn’t a real hot idea imo.